Why Is Celcuity Stock (CELC) Up 210% Today?
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The big news here is that the gedatolisib triplet showed statistically significant and clinically meaningful improvement in progression-free survival (PFS), reducing the risk of progression or death by 76% when compared to fulvestrant. The gedatolisib doublet also showed statistically significant and clinically meaningful improvement in PFS, reducing the risk of progression or death by 67% compared to fulvestrant.
Sara Hurvitz, co-investigator of the Celcuity clinical trial, said the results were 'potentially practice-changing.' She noted that 'we have not seen Phase 3 results in patients with HR-positive, HER2-negative advanced breast cancer before where there was a quadrupling of the likelihood of survival without disease progression relative to the study control.'
Celcuity Stock Movement Today
Celcuity stock was up 212.35% during pre-market trading on Monday, following a 1.99% dip on Friday. The company's shares were also up 5.19% year-to-date but down 23.29% over the past 12 months. Today's rally came with heavy trading, as some 5 million shares changed hands, compared to a three-month daily average of about 250,000 units.
Is Celcuity Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts' consensus rating for Celcuity is Strong Buy, based on seven Buy ratings over the past three months. With that comes an average CELC stock price target of $28.25, representing a potential 105.16% upside for the shares.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
7 minutes ago
- CNBC
Jim Cramer sees pockets of 'turmoil' in the market — plus, the latest on Nvidia's plans for China
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Tuesday's key moments. 1. Stocks were slightly lower Tuesday morning, giving up some of the modest gains seen earlier in the session. Even when the S & P 500 was in the green, Jim Cramer called out some "turmoil" underneath the hood of the market, particularly in the health-care sector. The biggest mover to the downside in that cohort is Novo Nordisk , with shares plunging more than 20% after the GLP-1 maker slashed its 2025 sales outlook. The company lowered growth expectations for Wegovy in the obesity market and for Ozempic in the diabetes market. Club holding Eli Lilly is down 4.3% in sympathy. We trimmed our position in the biopharma giant Tuesday to mitigate our risk ahead of Lilly's own earnings report next week. 2. Nvidia hit a 52-week high earlier in Tuesday's session on the back of a Reuters report that said the artificial intelligence leader has placed an order with Taiwan Semiconductor Manufacturing Co. for 300,000 of its made-for-China H20 chips. Earlier this month, the Trump administration reversed a ban imposed in April that prohibited sales of H20 chips to the Chinese market over national security concerns. The new orders with TSMC adds to the existing inventory of 600,000 to 700,000 H20 chips, Reuters reported. Elsewhere, fellow chipmakers Advanced Micro Devices and Club holding Broadcom were solidly higher, as earnings from the likes of Cadence Design Systems cast a positive due on the broader AI trade. 3. Coffee giant Starbucks reports its third quarter of fiscal 2025 after the bell Tuesday. We're hoping to see a boost in same-store sales in the locations where turnaround artist CEO Brian Niccol has rolled out his "Green Apron Service" model, a strategy aimed at enhancing the customer experience. We'd also like to see how the company's labor investments are helping business operations and what the plans for its growth China business. Jim said he's "still not expecting big stuff" this quarter given the company is still in the early stages of the turnaround . Starbucks shares, which have trailed the market this year, were down nearly 1% Tuesday. 4. Stocks covered in Tuesday's rapid fire at the end of the video were: Boeing , United Health , Procter & Gamble , Merck , and Cadence Design Systems. (Jim Cramer's Charitable Trust is long LLY, NVDA, SBUX. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Yahoo
9 minutes ago
- Yahoo
Celcuity shares triple on late-stage results for breast cancer therapy
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biotechnology firm Celcuity said Monday a late-stage trial testing its experimental breast cancer therapy in combination with other drugs succeeded, positioning the Minneapolis-based company to submit an approval application to the Food and Drug Administration later this year. Treatment involving the biotech's drug, called gedatolisib, significantly reduced the risk of disease progression or death in patients with a certain kind of advanced breast tumor that continued to grow despite initial therapy. Researchers observed this progression-free survival benefit in both patients given a 'doublet' drug combination including gedatolisib and a 'triplet' combination. In a statement, Celcuity said the trial achieved 'several new milestones' in testing of treatments for breast cancer that's positive for hormone receptors but negative for another protein called HER2. Co-principal investigator Sara Hurvitz, head of the hematology and oncology division at the University of Washington's Department of Medicine, called the results 'potentially practice-changing' in the company's statement. With results in hand, Celcuity plans to file in the fourth quarter for FDA approval. Shares in the company tripled in early trading Monday, before settling back to trade higher by almost 200%. The share price gain inflated Celcuity's market value to about $1.5 billion. Celcuity's study enrolled patients with HR+, HER2- tumors that tested negative for common mutations in a gene called PI3KCA. In one group, the company paired gedatolisib with Pfizer's Ibrance and AstraZeneca's Faslodex, which is available as generic fulvestrant. Treatment with the triplet reduced the risk of disease progression by 76% compared to fulvestrant alone. Progression-free survival reached a median of 9.3 months in the triplet group versus just 2 months for those on fulvestrant. Given with just fulvestrant, gedatolisib treatment reduced progression by 67%, leading to a median progression-free survival of 7.4 months. The company said patient discontinuation rates due to treatment-related adverse events was lower in this study than in Phase 3 trials for approved drug combinations for this patient population. Full data from the trial will be presented at an upcoming medical conference later this year. Andrew Berens, an analyst at Leerink Partners, wrote in a client note Monday that the data 'are likely clinically meaningful across multiple subgroups' and provide rationale to use Celcuity's drug as a second-line breast cancer treatment. 'The 7.3 and 5.4-months incremental improvement in median PFS relative to fulvestrant for the gedatolisib regimens are potentially paradigm-shifting results,' claimed Igor Gorbatchevsky, chief medical officer of Celcuity, in a statement. Other approved drug combinations in the second-line setting are supported by data showing lower median progression-free survival, of about two to four months, compared to the doublet and triplet regimens using gedatolisib. Celcuity expects to have data for gedatolisib in breast cancer patients with PIK3CA mutations by the end of this year. Recommended Reading Full Arvinas, Pfizer data confirm potential, limits of 'Protac' drug in breast cancer Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
SFL Missions Inc. Awarded Contract for Fast-Turnaround AISSat-4 Nanosatellite Development to Expand Capacity in Norwegian Maritime Monitoring System
TORONTO, July 29, 2025--(BUSINESS WIRE)--The Norwegian Space Agency (NOSA) has awarded a contract to SFL Missions Inc. to develop the AISSat-4 maritime ship tracking microsatellite for launch in less than one year. AISSat-4 is needed to expand operational capacity in Norway's maritime situational awareness network. AISSat-4 is being developed on SFL's SPARTAN 6U nanosatellite platform and will carry a single payload – a miniaturized Automatic Identification System (AIS) receiver built by Kongsberg Seatex of Trondheim, Norway. The SPARTAN bus is space proven with 18 commercial communications satellites previously deployed using this platform. SFL Missions is uniquely prepared to develop AISSat-4 on an accelerated schedule. Additionally, the SPARTAN platform relies on heritage hardware and software and is easily tailored to accommodate the AIS receiver and antennas. "We have extensive experience in implementing AIS missions, and therefore we have the expertise and design heritage needed to implement the AISSat-4 mission on a short schedule," said Dr. Robert E. Zee, SFL Missions Director and CEO. More broadly, he added, SFL Missions Inc. has the capacity to work on many satellite missions concurrently, and since the team is vertically integrated, it maintains full control over the subsystem and spacecraft level assembly, integration, and testing schedules. Under the leadership of NOSA and the Norwegian Coastal Administration, Norway operates the world's most extensive and sophisticated space-based marine monitoring system to protect the safety of vessels and sustainability of resources in its vast territorial waters. "The societal benefits we gain from collecting AIS information from satellites is significant. It is therefore important that we ensure the maintenance of this capability," said Coastal Administration Director Einar Vik Arset. "AISSat-4 will be a valuable addition at a time when several of our operational satellites are nearing the end of their expected lifespan." Norway launched the first ship-tracking satellite of its operational AISSat series in 2010 and then funded a parallel series of larger NorSat microsatellites. While the smaller AISSat nanosatellites each carry a single payload focused solely on collection of AIS signals, the NorSats each operate a ship-tracking device along with one or more technology demonstration payloads. NorSat-1 and -2 are both eight years old and have operated beyond their five-year design lives. Norway's leadership in space-based maritime monitoring includes eight spacecraft spanning more than 15 years, all of which were developed with SFL: AISSat-1 launched in 2010 with funding from Norwegian Defence Research Establishment (FFI) to prove that Automatic Identification System (AIS) signals from ships at sea could be detected by an AIS receiver in orbit. AISSat-1 was quickly transitioned to operational status where it collected data for 12 years. AISSat-2, a twin to AISSat-1, launched as an operational asset in 2014 until decommissioning nine years later. NorSat-1 and -2 launched in 2017, each carrying successively improved AIS receivers developed by Kongsberg Seatex. Additionally, NorSat-1 carries two experimental space science instruments, while NorSat-2 tested a two-way communication VHF data exchange device. NorSat-3 launched in 2021 with an experimental radar navigation detector to augment the ship-tracking capabilities of its AIS receiver. NorSat-TD launched in 2023 with a suite of technology demonstration payloads including a Dutch-built laser communications device that successfully enabled faster, more secure optical transmission of data between the spacecraft and ground station. NorSat-4 launched in January 2025 carrying a fifth-generation AIS receiver complemented by a first-of-its-kind low-light imaging camera to detect and identify "dark" ships not operating their AIS transponders. AISSat-4, now under development, will have the capacity to capture 1.5 million unique AIS signals every day even in crowded shipping lanes. Additionally, Norwegian AIS data collected from space will continue to serve as the mainstay of the Blue Justice Ocean Surveillance Program initiated by Norway in September 2023 to fight international fisheries crimes. Participants in this program share coastal data to uncover illegal fishing activities worldwide. About SFL Missions Inc. ( SFL Missions Inc. generates bigger returns from smaller, lower cost satellites. SFL Missions pushes the performance envelope and disrupts the traditional cost paradigm. We build quality small satellites at low cost that work the first time and enable NewSpace companies to mass produce through our Flex Production program. Satellites are built with advanced power systems, stringent attitude control and high-volume data capacity that are striking relative to the budget. We arrange launches globally and maintain a mission control center accessing ground stations worldwide. The pioneering and barrier-breaking work of SFL Missions is a key enabler to tomorrow's cost-aggressive satellites and constellations. View source version on Contacts Dr. Robert E. ZeeSFL Missions Follow SFL Missions X @SFLMissionsInstagram at Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
